Under the so-called ‘Bolar' exemption, clinical
trials for generics and biosimilars are exempt from infringement.
In some European countries, including the UK, the exemption even
extends to innovative products.
Introduction
In order to market a medicinal product, a manufacturer must
first obtain regulatory approval by conducting clinical tests and
trials to prove that the product is safe and effective. However,
when the medicinal product is a generic (1) or biosimilar (2)
product, a company can avoid having to carry out full trials by
relying on at least some of the data submitted by the original
applicant for marketing authorisation in connection with the
original (reference) medicinal product. To use this so-called
abridged procedure for obtaining marketing authorisation, however,
it is necessary to demonstrate that the generic/ biosimilar version
is bioequivalent to the approved reference medicine.